Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Income from Continuing Operations (2020 - 2025)

Historic Income from Continuing Operations for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to -$24.3 million.

  • Janux Therapeutics' Income from Continuing Operations rose 1335.04% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.9 million, marking a year-over-year decrease of 6832.13%. This contributed to the annual value of -$69.0 million for FY2024, which is 1835.73% down from last year.
  • Per Janux Therapeutics' latest filing, its Income from Continuing Operations stood at -$24.3 million for Q3 2025, which was up 1335.04% from -$33.9 million recorded in Q2 2025.
  • Janux Therapeutics' 5-year Income from Continuing Operations high stood at -$2.3 million for Q1 2021, and its period low was -$33.9 million during Q2 2025.
  • Moreover, its 5-year median value for Income from Continuing Operations was -$16.1 million (2022), whereas its average is -$16.0 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first plummeted by 75716.56% in 2021, then surged by 6596.41% in 2024.
  • Over the past 5 years, Janux Therapeutics' Income from Continuing Operations (Quarter) stood at -$13.4 million in 2021, then fell by 19.75% to -$16.1 million in 2022, then grew by 26.81% to -$11.8 million in 2023, then tumbled by 71.93% to -$20.2 million in 2024, then dropped by 20.27% to -$24.3 million in 2025.
  • Its Income from Continuing Operations stands at -$24.3 million for Q3 2025, versus -$33.9 million for Q2 2025 and -$23.5 million for Q1 2025.